Welcome to our dedicated page for Hookipa Pharma news (Ticker: HOOK), a resource for investors and traders seeking the latest updates and insights on Hookipa Pharma stock.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company pioneering arenavirus-based immunotherapies for cancer and infectious diseases. This page aggregates official announcements, including clinical trial updates, regulatory milestones, and strategic partnerships, providing investors and researchers a centralized resource for tracking the company’s progress.
Users will find timely updates on HOOKIPA’s Vaxwave® and Therat® platforms, which leverage viral vector technology to stimulate durable immune responses. Key content includes trial results for HPV16+ head and neck cancer therapies, hepatitis B/HIV collaboration updates, and financial disclosures. The platform’s stakeholders to monitor developments in immunotherapy approaches designed to overcome traditional treatment limitations.
Bookmark this page for direct access to press releases, SEC filings, and event transcripts. Check regularly for updates on HOOKIPA’s pipeline advancements and industry collaborations that shape its position in the immuno-oncology landscape.
HOOKIPA Pharma announced updated Phase 2 clinical data for HB-200 combined with pembrolizumab in treating recurrent/metastatic HPV16+ head and neck cancer at the ASCO 2024 Annual Meeting. Out of 35 evaluable patients, results showed a 37% confirmed objective response rate (ORR), 11% complete response (CR) rate, and 69% disease control rate (DCR). Notably, in a subset of 17 patients with a PD-L1 CPS of 20 or higher, the ORR was 53%, CR rate 18%, and DCR 82%. Preliminary progression-free survival (PFS) for this subset was 16.3 months, with a 9-month overall survival (OS) rate of 88%. The treatment was generally well-tolerated, with Grade ≥3 treatment-related adverse events reported in 15% of patients. The pivotal Phase 2/3 trial is set to begin in Q4 2024.
HOOKIPA Pharma (NASDAQ: HOOK) will host an investor call on June 4, 2024, at 4:15 p.m. ET to discuss promising preliminary results from its Phase 2 clinical trial of HB-200 in combination with pembrolizumab.
The data, presented at the American Society of Clinical Oncology 2024 Annual Meeting, focuses on progression-free survival and overall survival for patients with a Combined Positive Score (CPS) ≥20, targeting human papillomavirus 16 positive head and neck cancer.
The company's proprietary arenavirus platform underpins this new class of immunotherapeutics.
HOOKIPA Pharma announced positive results from its Phase 1/2 trial of HB-200 for HPV16+ head and neck cancers, to be presented at ASCO 2024. The study, which involved 42 patients, showed an objective response rate (ORR) of 53% and a disease control rate (DCR) of 82% among patients with PD-L1 CPS of 20 or higher. HB-200 combined with pembrolizumab exhibited a favorable safety profile, with no treatment-related deaths and low treatment discontinuation rates. Additional data, including preliminary progression-free survival and overall survival, will be presented on June 4, 2024. Preliminary findings from an investigator-initiated trial for HB-200 with chemotherapy in non-metastatic HPV16+ cancers showed promising results, with an 81% deep response rate. Preclinical data for HB-700, targeting KRAS mutations, demonstrated effective T-cell responses and tumor cell killing in mice.
HOOKIPA Pharma Inc. reported its first quarter 2024 financial results and business highlights, focusing on its pivotal trial design for HB-200 in combination with pembrolizumab for HPV16+ recurrent or metastatic OPSCC. The company received FDA clearance for its IND application for HB-700 for KRAS mutated cancers. Financially, HOOKIPA saw total revenues of $36.6 million, driven by milestone payments, resulting in a profitable quarter.